IN2013MU02828A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02828A
IN2013MU02828A IN2828MU2013A IN2013MU02828A IN 2013MU02828 A IN2013MU02828 A IN 2013MU02828A IN 2828MU2013 A IN2828MU2013 A IN 2828MU2013A IN 2013MU02828 A IN2013MU02828 A IN 2013MU02828A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
saroglitazar
present
free acid
amorphous form
Prior art date
Application number
Other languages
English (en)
Inventor
Shriprakash Dhar Dwivedi
Ramesh Chandra Singh
Vikas Patel
Amar Rajendra Desai
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2828MU2013 priority Critical patent/IN2013MU02828A/en
Priority to PCT/IN2014/000551 priority patent/WO2015029066A1/en
Priority to EP14802513.3A priority patent/EP3039011A1/en
Priority to US14/915,457 priority patent/US9951009B2/en
Priority to MX2016002612A priority patent/MX371021B/es
Publication of IN2013MU02828A publication Critical patent/IN2013MU02828A/en
Priority to PH12016500394A priority patent/PH12016500394A1/en
Priority to ZA2016/01461A priority patent/ZA201601461B/en
Priority to US15/947,044 priority patent/US20180297945A1/en
Priority to US15/947,049 priority patent/US20180297946A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2828MU2013 2013-08-29 2014-08-28 IN2013MU02828A (enEXAMPLES)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN2828MU2013 IN2013MU02828A (enEXAMPLES) 2013-08-29 2014-08-28
PCT/IN2014/000551 WO2015029066A1 (en) 2013-08-29 2014-08-28 Polymorphic form of pyrrole derivative and intermediate thereof
EP14802513.3A EP3039011A1 (en) 2013-08-29 2014-08-28 Polymorphic form of pyrrole derivative and intermediate thereof
US14/915,457 US9951009B2 (en) 2013-08-29 2014-08-28 Polymorphic form of pyrrole derivative and intermediate thereof
MX2016002612A MX371021B (es) 2013-08-29 2014-08-28 Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
PH12016500394A PH12016500394A1 (en) 2013-08-29 2016-02-29 Polymorphic form of pyrrole derivative and intermediate thereof
ZA2016/01461A ZA201601461B (en) 2013-08-29 2016-03-03 Polymorphic form of pyrrole derivative and intermediate thereof
US15/947,044 US20180297945A1 (en) 2013-08-29 2018-04-06 Polymorphic form of pyrrole derivative and intermediate thereof
US15/947,049 US20180297946A1 (en) 2013-08-29 2018-04-06 Polymorphic form of pyrrole derivative and intermediate thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2828MU2013 IN2013MU02828A (enEXAMPLES) 2013-08-29 2014-08-28

Publications (1)

Publication Number Publication Date
IN2013MU02828A true IN2013MU02828A (enEXAMPLES) 2015-07-03

Family

ID=51947417

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2828MU2013 IN2013MU02828A (enEXAMPLES) 2013-08-29 2014-08-28

Country Status (7)

Country Link
US (3) US9951009B2 (enEXAMPLES)
EP (1) EP3039011A1 (enEXAMPLES)
IN (1) IN2013MU02828A (enEXAMPLES)
MX (1) MX371021B (enEXAMPLES)
PH (1) PH12016500394A1 (enEXAMPLES)
WO (1) WO2015029066A1 (enEXAMPLES)
ZA (1) ZA201601461B (enEXAMPLES)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
JP6246895B2 (ja) 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）のための新規組成物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enEXAMPLES) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US20180125816A1 (en) * 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
US11242321B2 (en) * 2018-01-30 2022-02-08 Kainos Medicine Inc. Salt forms of organic compound
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent
US12201611B2 (en) * 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713494B1 (en) * 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
CA2316841C (en) * 1998-01-07 2007-11-20 Meiji Seika Kaisha Ltd. Crystallographically stable amorphous cephalosporin compositions and process for producing the same
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
US6627760B1 (en) * 2001-06-25 2003-09-30 Astrazeneca Ab Amorphous compound
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US20040132743A1 (en) * 2002-06-21 2004-07-08 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories, Inc. Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride)
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
BRPI0407038A (pt) * 2003-01-27 2006-01-17 Hanmi Pharm Ind Co Ltd Camsilato de amlodipina amorfo estável, processo para a preparação do mesmo e composição para administração oral deste
US20040266787A1 (en) * 2003-03-25 2004-12-30 Dr. Reddy's Laboratories Limited Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof
UA84881C2 (ru) * 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
WO2007016435A2 (en) * 2005-07-28 2007-02-08 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

Also Published As

Publication number Publication date
MX2016002612A (es) 2016-10-04
PH12016500394A1 (en) 2016-05-16
EP3039011A1 (en) 2016-07-06
ZA201601461B (en) 2017-05-31
US20180297945A1 (en) 2018-10-18
US20180297946A1 (en) 2018-10-18
US9951009B2 (en) 2018-04-24
MX371021B (es) 2020-01-13
US20160207884A1 (en) 2016-07-21
WO2015029066A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
MY175854A (en) Novel quinolone derivatives
IN2014MN02106A (enEXAMPLES)
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12014502040A1 (en) Heterocyclyl compounds
IN2014MN02598A (enEXAMPLES)
IN2014CN04530A (enEXAMPLES)
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
PH12016500885A1 (en) Novel heterocyclic compounds
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MY162397A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
IN2014MN02380A (enEXAMPLES)
PH12017500089A1 (en) Aldosterone synthase inhibitors
IN2014DN08296A (enEXAMPLES)
PH12016500980B1 (en) Amide derivatives for gpr119 agonist
IN2014MN02433A (enEXAMPLES)
WO2015102017A8 (en) Processes for the preparation of lorcaserin
WO2014106826A3 (en) Anthracycline analogue and uses thereof
IN2013MU03838A (enEXAMPLES)